Project Details
Description
A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid??) Regimen or A Sequential Azacitidine (Vidaza??) plus Lenalidomide (Revlimid??) Regimen versus Leukemia (CC-5013-AML-001)
| Status | Finished |
|---|---|
| Effective start/end date | 10/17/12 → 12/31/17 |
Funding
- CELGENE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.